{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["sacituzumab tirumotecan (SKB264)","osimertinib"]],"indication":"first-line EGFR-mutated locally advanced or metastatic non-squamous NSCLC","name":"NCT06670196","nct_id":"NCT06670196","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06670196. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive SKB264 on Day 1 and Day 15 of each 4-week cycle, Osimertinib once-daily for each 4-week cycle.","label":"SKB264+Osimertinib","type":"EXPERIMENTAL"},{"description":"Participants will receive Osimertinib once-daily for each 4-week cycle.","label":"Osimertinib","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-07","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":420,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"SKB264","otherNames":[],"type":"DRUG"},{"name":"Osimertinib","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-10","lead_sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","official_title":"A Randomized, Open-Label, Multicenter, Phase III Clinical Study of SKB264 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR)","timeFrame":"Randomization up to approximately 36 months"}],"references":[],"start_date":{"date":"2024-11-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT06670196"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06670196"}